Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease.
Cho
Roy
R
Department of Medicine, Western Pennsylvania Hospital, Pittsburgh, Pennsylvania 15224, USA. rc3250@hotmail.com
Javed
Nosheen
N
Traub
Darren
D
Kodali
Sobhan
S
Atem
Folefac
F
Srinivasan
Venkatraman
V
D000111:Acetylcysteine / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D001639:Bicarbonates / Q000008:administration & dosage* / Q000627:therapeutic use; D002021:Buffers; D016001:Confidence Intervals; D003287:Contrast Media / Q000009:adverse effects*; D018592:Cross-Over Studies; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D007902:Length of Stay; D008297:Male
D001639:Bicarbonates; D002021:Buffers; D003287:Contrast Media; D016166:Free Radical Scavengers; D000111:Acetylcysteine